Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Lilly promotes CFO Rice to executive VP

Derica Rice has been appointed the executive vice president of Eli Lilly with expanded responsibilities in the companys global services sector.

MGH fellow wins AHA resuscitation award

Patrick Sips, PhD, a research fellow in the department of anesthesiology and critical care at Massachusetts General Hospital (MGH) in Boston, was awarded the third annual American Heart Association-Philips Healthcare Resuscitation Fellowship Award.

Industry-physician conflicts of interest continue to be probed

Sen. Chuck Grassley, R-Iowa, has recently reinforced his crusade to inquire into potential conflicts of interest between industry and physicians. Concurrently, the state of New Jersey has issued recommendations, placing the burden of disclosure of industry payments on physicians.

Array BioPharm, Amgen ink $60M type 2 diabetes drug deal

Array BioPharma and Amgen have entered into an agreement granting Amgen exclusive worldwide rights to Array's small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with type 2 diabetes.

Gilead's hypertension drug fails to hit clinical endpoints; gets shelved

A clinical trial investigating the use of Gilead Sciences' endothelin receptor antagonist darusentan as therapy for resistant hypertension found that the treatment missed its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (BP) and diastolic BP when compared to a placebo.

Bristol-Myers names Bancroft as interim CFO, in lieu of Huet's departure

Pharmaceutical company Bristol-Myers Squibb has selected Charles Bancroft as its acting chief financial officer (CFO), as its current executive vice president and CFO, Jean-Marc Huet, prepares to leave his post at the end of this year.

Resuscitation science advances, more education needed

The science of resuscitation has advanced considerably in the past few decades. Yet, cardiac arrest survival at home or work has remained unchanged in that time. Not many homes are equipped with automated external defibrillators (AEDs), but many workplaces are. These devices are capable of directing bystanders to not only adequately shock patients, but also to perform life-saving CPR.

AHA: Continuous chest compression-CPR, without mouth-to-mouth, improves survival

The chance of surviving a cardiac arrest outside a hospital was found to be twice as high when bystanders performed continuous chest compressions without mouth-to-mouth breathing than when bystanders performed standard CPR. These are the latest findings reported by the Resuscitation Research Group at the University of Arizona Sarver Heart Center and the SHARE Program (Save Hearts in Arizona Research and Education) at the Arizona Department of Health Services.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup